nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—AHR—atherosclerosis	0.493	1	CbGaD
Leflunomide—ABCG2—Rosuvastatin—atherosclerosis	0.0717	0.232	CbGbCtD
Leflunomide—ABCG2—Ezetimibe—atherosclerosis	0.0717	0.232	CbGbCtD
Leflunomide—ABCG2—Pravastatin—atherosclerosis	0.0652	0.211	CbGbCtD
Leflunomide—CYP2C9—Rosuvastatin—atherosclerosis	0.0266	0.0864	CbGbCtD
Leflunomide—CYP2C9—Simvastatin—atherosclerosis	0.0248	0.0803	CbGbCtD
Leflunomide—CYP2C9—Pravastatin—atherosclerosis	0.0242	0.0786	CbGbCtD
Leflunomide—CYP2C9—Lovastatin—atherosclerosis	0.0242	0.0786	CbGbCtD
Leflunomide—Niflumic Acid—PLA2G1B—atherosclerosis	0.00359	0.886	CrCbGaD
Leflunomide—DHODH—Lovastatin—Pravastatin—atherosclerosis	0.00204	0.5	CbGdCrCtD
Leflunomide—DHODH—Lovastatin—Simvastatin—atherosclerosis	0.00204	0.5	CbGdCrCtD
Leflunomide—Niflumic Acid—PTGS2—atherosclerosis	0.00046	0.114	CrCbGaD
Leflunomide—Muscle spasms—Lovastatin—atherosclerosis	0.000243	0.00188	CcSEcCtD
Leflunomide—Infection—Rosuvastatin—atherosclerosis	0.000242	0.00188	CcSEcCtD
Leflunomide—Alopecia—Simvastatin—atherosclerosis	0.00024	0.00186	CcSEcCtD
Leflunomide—Back pain—Ezetimibe—atherosclerosis	0.00024	0.00186	CcSEcCtD
Leflunomide—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000239	0.00185	CcSEcCtD
Leflunomide—Muscle spasms—Ezetimibe—atherosclerosis	0.000238	0.00185	CcSEcCtD
Leflunomide—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000238	0.00185	CcSEcCtD
Leflunomide—Vision blurred—Lovastatin—atherosclerosis	0.000238	0.00185	CcSEcCtD
Leflunomide—Mental disorder—Simvastatin—atherosclerosis	0.000238	0.00185	CcSEcCtD
Leflunomide—Ill-defined disorder—Lovastatin—atherosclerosis	0.000234	0.00182	CcSEcCtD
Leflunomide—Eye disorder—Niacin—atherosclerosis	0.000233	0.00181	CcSEcCtD
Leflunomide—Flatulence—Simvastatin—atherosclerosis	0.000233	0.00181	CcSEcCtD
Leflunomide—Erythema multiforme—Pravastatin—atherosclerosis	0.000232	0.0018	CcSEcCtD
Leflunomide—Dysgeusia—Simvastatin—atherosclerosis	0.000231	0.0018	CcSEcCtD
Leflunomide—Angioedema—Lovastatin—atherosclerosis	0.000231	0.00179	CcSEcCtD
Leflunomide—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00023	0.00178	CcSEcCtD
Leflunomide—Anaemia—Ezetimibe—atherosclerosis	0.000229	0.00178	CcSEcCtD
Leflunomide—Malaise—Lovastatin—atherosclerosis	0.000228	0.00177	CcSEcCtD
Leflunomide—Cardiac disorder—Pravastatin—atherosclerosis	0.000228	0.00177	CcSEcCtD
Leflunomide—Muscle spasms—Simvastatin—atherosclerosis	0.000227	0.00176	CcSEcCtD
Leflunomide—Vertigo—Lovastatin—atherosclerosis	0.000227	0.00176	CcSEcCtD
Leflunomide—Angioedema—Ezetimibe—atherosclerosis	0.000226	0.00176	CcSEcCtD
Leflunomide—Leukopenia—Lovastatin—atherosclerosis	0.000226	0.00175	CcSEcCtD
Leflunomide—Chills—Niacin—atherosclerosis	0.000224	0.00174	CcSEcCtD
Leflunomide—Malaise—Ezetimibe—atherosclerosis	0.000223	0.00173	CcSEcCtD
Leflunomide—Vision blurred—Simvastatin—atherosclerosis	0.000223	0.00173	CcSEcCtD
Leflunomide—Arrhythmia—Niacin—atherosclerosis	0.000223	0.00173	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000222	0.00172	CcSEcCtD
Leflunomide—Alopecia—Niacin—atherosclerosis	0.00022	0.00171	CcSEcCtD
Leflunomide—Chills—Pravastatin—atherosclerosis	0.00022	0.00171	CcSEcCtD
Leflunomide—Insomnia—Rosuvastatin—atherosclerosis	0.00022	0.00171	CcSEcCtD
Leflunomide—Ill-defined disorder—Simvastatin—atherosclerosis	0.000219	0.0017	CcSEcCtD
Leflunomide—Arrhythmia—Pravastatin—atherosclerosis	0.000219	0.0017	CcSEcCtD
Leflunomide—Palpitations—Ezetimibe—atherosclerosis	0.000219	0.0017	CcSEcCtD
Leflunomide—Paraesthesia—Rosuvastatin—atherosclerosis	0.000218	0.0017	CcSEcCtD
Leflunomide—Anaemia—Simvastatin—atherosclerosis	0.000218	0.00169	CcSEcCtD
Leflunomide—Malnutrition—Niacin—atherosclerosis	0.000217	0.00168	CcSEcCtD
Leflunomide—Alopecia—Pravastatin—atherosclerosis	0.000217	0.00168	CcSEcCtD
Leflunomide—Cough—Ezetimibe—atherosclerosis	0.000216	0.00168	CcSEcCtD
Leflunomide—Angioedema—Simvastatin—atherosclerosis	0.000216	0.00168	CcSEcCtD
Leflunomide—Chest pain—Lovastatin—atherosclerosis	0.000215	0.00167	CcSEcCtD
Leflunomide—Myalgia—Lovastatin—atherosclerosis	0.000215	0.00167	CcSEcCtD
Leflunomide—Arthralgia—Lovastatin—atherosclerosis	0.000215	0.00167	CcSEcCtD
Leflunomide—Anxiety—Lovastatin—atherosclerosis	0.000214	0.00166	CcSEcCtD
Leflunomide—Dyspepsia—Rosuvastatin—atherosclerosis	0.000214	0.00166	CcSEcCtD
Leflunomide—Hypertension—Ezetimibe—atherosclerosis	0.000214	0.00166	CcSEcCtD
Leflunomide—Flatulence—Niacin—atherosclerosis	0.000214	0.00166	CcSEcCtD
Leflunomide—Malaise—Simvastatin—atherosclerosis	0.000213	0.00165	CcSEcCtD
Leflunomide—Discomfort—Lovastatin—atherosclerosis	0.000212	0.00165	CcSEcCtD
Leflunomide—Vertigo—Simvastatin—atherosclerosis	0.000212	0.00165	CcSEcCtD
Leflunomide—Leukopenia—Simvastatin—atherosclerosis	0.000211	0.00164	CcSEcCtD
Leflunomide—Arthralgia—Ezetimibe—atherosclerosis	0.000211	0.00164	CcSEcCtD
Leflunomide—Chest pain—Ezetimibe—atherosclerosis	0.000211	0.00164	CcSEcCtD
Leflunomide—Myalgia—Ezetimibe—atherosclerosis	0.000211	0.00164	CcSEcCtD
Leflunomide—Flatulence—Pravastatin—atherosclerosis	0.00021	0.00163	CcSEcCtD
Leflunomide—Dry mouth—Lovastatin—atherosclerosis	0.00021	0.00163	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000209	0.00163	CcSEcCtD
Leflunomide—Dysgeusia—Pravastatin—atherosclerosis	0.000209	0.00162	CcSEcCtD
Leflunomide—Muscle spasms—Niacin—atherosclerosis	0.000209	0.00162	CcSEcCtD
Leflunomide—Discomfort—Ezetimibe—atherosclerosis	0.000208	0.00162	CcSEcCtD
Leflunomide—Pain—Rosuvastatin—atherosclerosis	0.000208	0.00161	CcSEcCtD
Leflunomide—Constipation—Rosuvastatin—atherosclerosis	0.000208	0.00161	CcSEcCtD
Leflunomide—Dry mouth—Ezetimibe—atherosclerosis	0.000206	0.0016	CcSEcCtD
Leflunomide—Anaphylactic shock—Lovastatin—atherosclerosis	0.000206	0.0016	CcSEcCtD
Leflunomide—Muscle spasms—Pravastatin—atherosclerosis	0.000205	0.00159	CcSEcCtD
Leflunomide—Infection—Lovastatin—atherosclerosis	0.000205	0.00159	CcSEcCtD
Leflunomide—Vision blurred—Niacin—atherosclerosis	0.000204	0.00159	CcSEcCtD
Leflunomide—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000202	0.00157	CcSEcCtD
Leflunomide—Thrombocytopenia—Lovastatin—atherosclerosis	0.000202	0.00157	CcSEcCtD
Leflunomide—Vision blurred—Pravastatin—atherosclerosis	0.000201	0.00156	CcSEcCtD
Leflunomide—Chest pain—Simvastatin—atherosclerosis	0.000201	0.00156	CcSEcCtD
Leflunomide—Myalgia—Simvastatin—atherosclerosis	0.000201	0.00156	CcSEcCtD
Leflunomide—Arthralgia—Simvastatin—atherosclerosis	0.000201	0.00156	CcSEcCtD
Leflunomide—Infection—Ezetimibe—atherosclerosis	0.000201	0.00156	CcSEcCtD
Leflunomide—Feeling abnormal—Rosuvastatin—atherosclerosis	0.0002	0.00156	CcSEcCtD
Leflunomide—Anxiety—Simvastatin—atherosclerosis	0.0002	0.00156	CcSEcCtD
Leflunomide—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000199	0.00154	CcSEcCtD
Leflunomide—Discomfort—Simvastatin—atherosclerosis	0.000199	0.00154	CcSEcCtD
Leflunomide—Nervous system disorder—Ezetimibe—atherosclerosis	0.000198	0.00154	CcSEcCtD
Leflunomide—Angioedema—Niacin—atherosclerosis	0.000198	0.00154	CcSEcCtD
Leflunomide—Ill-defined disorder—Pravastatin—atherosclerosis	0.000198	0.00154	CcSEcCtD
Leflunomide—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000198	0.00154	CcSEcCtD
Leflunomide—Anaemia—Pravastatin—atherosclerosis	0.000197	0.00153	CcSEcCtD
Leflunomide—Anorexia—Lovastatin—atherosclerosis	0.000197	0.00152	CcSEcCtD
Leflunomide—Skin disorder—Ezetimibe—atherosclerosis	0.000196	0.00152	CcSEcCtD
Leflunomide—Angioedema—Pravastatin—atherosclerosis	0.000195	0.00151	CcSEcCtD
Leflunomide—Vertigo—Niacin—atherosclerosis	0.000195	0.00151	CcSEcCtD
Leflunomide—Leukopenia—Niacin—atherosclerosis	0.000194	0.00151	CcSEcCtD
Leflunomide—Urticaria—Rosuvastatin—atherosclerosis	0.000193	0.0015	CcSEcCtD
Leflunomide—Anaphylactic shock—Simvastatin—atherosclerosis	0.000193	0.0015	CcSEcCtD
Leflunomide—Malaise—Pravastatin—atherosclerosis	0.000193	0.00149	CcSEcCtD
Leflunomide—Abdominal pain—Rosuvastatin—atherosclerosis	0.000192	0.00149	CcSEcCtD
Leflunomide—Vertigo—Pravastatin—atherosclerosis	0.000192	0.00149	CcSEcCtD
Leflunomide—Palpitations—Niacin—atherosclerosis	0.000192	0.00149	CcSEcCtD
Leflunomide—Infection—Simvastatin—atherosclerosis	0.000192	0.00149	CcSEcCtD
Leflunomide—Leukopenia—Pravastatin—atherosclerosis	0.000191	0.00148	CcSEcCtD
Leflunomide—Cough—Niacin—atherosclerosis	0.000189	0.00147	CcSEcCtD
Leflunomide—Thrombocytopenia—Simvastatin—atherosclerosis	0.000189	0.00147	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000188	0.00146	CcSEcCtD
Leflunomide—Insomnia—Lovastatin—atherosclerosis	0.000186	0.00145	CcSEcCtD
Leflunomide—Cough—Pravastatin—atherosclerosis	0.000186	0.00145	CcSEcCtD
Leflunomide—Paraesthesia—Lovastatin—atherosclerosis	0.000185	0.00144	CcSEcCtD
Leflunomide—Myalgia—Niacin—atherosclerosis	0.000185	0.00143	CcSEcCtD
Leflunomide—Arthralgia—Niacin—atherosclerosis	0.000185	0.00143	CcSEcCtD
Leflunomide—Hypertension—Pravastatin—atherosclerosis	0.000184	0.00143	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000184	0.00143	CcSEcCtD
Leflunomide—Anorexia—Simvastatin—atherosclerosis	0.000184	0.00143	CcSEcCtD
Leflunomide—Dyspnoea—Lovastatin—atherosclerosis	0.000184	0.00143	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000183	0.00142	CcSEcCtD
Leflunomide—Insomnia—Ezetimibe—atherosclerosis	0.000183	0.00142	CcSEcCtD
Leflunomide—Myalgia—Pravastatin—atherosclerosis	0.000182	0.00141	CcSEcCtD
Leflunomide—Arthralgia—Pravastatin—atherosclerosis	0.000182	0.00141	CcSEcCtD
Leflunomide—Chest pain—Pravastatin—atherosclerosis	0.000182	0.00141	CcSEcCtD
Leflunomide—Paraesthesia—Ezetimibe—atherosclerosis	0.000182	0.00141	CcSEcCtD
Leflunomide—Dyspepsia—Lovastatin—atherosclerosis	0.000181	0.00141	CcSEcCtD
Leflunomide—Anxiety—Pravastatin—atherosclerosis	0.000181	0.00141	CcSEcCtD
Leflunomide—Dry mouth—Niacin—atherosclerosis	0.000181	0.0014	CcSEcCtD
Leflunomide—Dyspnoea—Ezetimibe—atherosclerosis	0.00018	0.0014	CcSEcCtD
Leflunomide—Discomfort—Pravastatin—atherosclerosis	0.00018	0.00139	CcSEcCtD
Leflunomide—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000179	0.00139	CcSEcCtD
Leflunomide—Decreased appetite—Lovastatin—atherosclerosis	0.000179	0.00139	CcSEcCtD
Leflunomide—Dyspepsia—Ezetimibe—atherosclerosis	0.000178	0.00138	CcSEcCtD
Leflunomide—Fatigue—Lovastatin—atherosclerosis	0.000178	0.00138	CcSEcCtD
Leflunomide—Anaphylactic shock—Niacin—atherosclerosis	0.000177	0.00137	CcSEcCtD
Leflunomide—Pain—Lovastatin—atherosclerosis	0.000176	0.00137	CcSEcCtD
Leflunomide—Constipation—Lovastatin—atherosclerosis	0.000176	0.00137	CcSEcCtD
Leflunomide—Decreased appetite—Ezetimibe—atherosclerosis	0.000176	0.00136	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000176	0.00136	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000175	0.00135	CcSEcCtD
Leflunomide—Asthenia—Rosuvastatin—atherosclerosis	0.000175	0.00135	CcSEcCtD
Leflunomide—Insomnia—Simvastatin—atherosclerosis	0.000174	0.00135	CcSEcCtD
Leflunomide—Anaphylactic shock—Pravastatin—atherosclerosis	0.000174	0.00135	CcSEcCtD
Leflunomide—Fatigue—Ezetimibe—atherosclerosis	0.000174	0.00135	CcSEcCtD
Leflunomide—Infection—Pravastatin—atherosclerosis	0.000173	0.00134	CcSEcCtD
Leflunomide—Paraesthesia—Simvastatin—atherosclerosis	0.000173	0.00134	CcSEcCtD
Leflunomide—Pain—Ezetimibe—atherosclerosis	0.000173	0.00134	CcSEcCtD
Leflunomide—Constipation—Ezetimibe—atherosclerosis	0.000173	0.00134	CcSEcCtD
Leflunomide—Tachycardia—Niacin—atherosclerosis	0.000173	0.00134	CcSEcCtD
Leflunomide—Pruritus—Rosuvastatin—atherosclerosis	0.000172	0.00134	CcSEcCtD
Leflunomide—Skin disorder—Niacin—atherosclerosis	0.000172	0.00133	CcSEcCtD
Leflunomide—Dyspnoea—Simvastatin—atherosclerosis	0.000172	0.00133	CcSEcCtD
Leflunomide—Hyperhidrosis—Niacin—atherosclerosis	0.000171	0.00133	CcSEcCtD
Leflunomide—Thrombocytopenia—Pravastatin—atherosclerosis	0.000171	0.00132	CcSEcCtD
Leflunomide—Feeling abnormal—Lovastatin—atherosclerosis	0.00017	0.00132	CcSEcCtD
Leflunomide—Dyspepsia—Simvastatin—atherosclerosis	0.00017	0.00132	CcSEcCtD
Leflunomide—Anorexia—Niacin—atherosclerosis	0.000169	0.00131	CcSEcCtD
Leflunomide—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000169	0.00131	CcSEcCtD
Leflunomide—Hyperhidrosis—Pravastatin—atherosclerosis	0.000169	0.00131	CcSEcCtD
Leflunomide—Decreased appetite—Simvastatin—atherosclerosis	0.000168	0.0013	CcSEcCtD
Leflunomide—Feeling abnormal—Ezetimibe—atherosclerosis	0.000167	0.00129	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000166	0.00129	CcSEcCtD
Leflunomide—Diarrhoea—Rosuvastatin—atherosclerosis	0.000166	0.00129	CcSEcCtD
Leflunomide—Fatigue—Simvastatin—atherosclerosis	0.000166	0.00129	CcSEcCtD
Leflunomide—Anorexia—Pravastatin—atherosclerosis	0.000166	0.00129	CcSEcCtD
Leflunomide—Hypotension—Niacin—atherosclerosis	0.000165	0.00128	CcSEcCtD
Leflunomide—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000165	0.00128	CcSEcCtD
Leflunomide—Pain—Simvastatin—atherosclerosis	0.000165	0.00128	CcSEcCtD
Leflunomide—Constipation—Simvastatin—atherosclerosis	0.000165	0.00128	CcSEcCtD
Leflunomide—Urticaria—Lovastatin—atherosclerosis	0.000164	0.00127	CcSEcCtD
Leflunomide—Body temperature increased—Lovastatin—atherosclerosis	0.000163	0.00126	CcSEcCtD
Leflunomide—Abdominal pain—Lovastatin—atherosclerosis	0.000163	0.00126	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000161	0.00125	CcSEcCtD
Leflunomide—Dizziness—Rosuvastatin—atherosclerosis	0.000161	0.00125	CcSEcCtD
Leflunomide—Urticaria—Ezetimibe—atherosclerosis	0.000161	0.00125	CcSEcCtD
Leflunomide—Insomnia—Niacin—atherosclerosis	0.00016	0.00124	CcSEcCtD
Leflunomide—Abdominal pain—Ezetimibe—atherosclerosis	0.00016	0.00124	CcSEcCtD
Leflunomide—Body temperature increased—Ezetimibe—atherosclerosis	0.00016	0.00124	CcSEcCtD
Leflunomide—Paraesthesia—Niacin—atherosclerosis	0.000159	0.00123	CcSEcCtD
Leflunomide—Feeling abnormal—Simvastatin—atherosclerosis	0.000159	0.00123	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000159	0.00123	CcSEcCtD
Leflunomide—Dyspnoea—Niacin—atherosclerosis	0.000158	0.00122	CcSEcCtD
Leflunomide—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000158	0.00122	CcSEcCtD
Leflunomide—Insomnia—Pravastatin—atherosclerosis	0.000158	0.00122	CcSEcCtD
Leflunomide—Paraesthesia—Pravastatin—atherosclerosis	0.000157	0.00121	CcSEcCtD
Leflunomide—Dyspepsia—Niacin—atherosclerosis	0.000156	0.00121	CcSEcCtD
Leflunomide—Dyspnoea—Pravastatin—atherosclerosis	0.000155	0.00121	CcSEcCtD
Leflunomide—Decreased appetite—Niacin—atherosclerosis	0.000154	0.00119	CcSEcCtD
Leflunomide—Dyspepsia—Pravastatin—atherosclerosis	0.000153	0.00119	CcSEcCtD
Leflunomide—Rash—Rosuvastatin—atherosclerosis	0.000153	0.00119	CcSEcCtD
Leflunomide—Dermatitis—Rosuvastatin—atherosclerosis	0.000153	0.00119	CcSEcCtD
Leflunomide—Urticaria—Simvastatin—atherosclerosis	0.000153	0.00119	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Niacin—atherosclerosis	0.000153	0.00119	CcSEcCtD
Leflunomide—Abdominal pain—Simvastatin—atherosclerosis	0.000152	0.00118	CcSEcCtD
Leflunomide—Body temperature increased—Simvastatin—atherosclerosis	0.000152	0.00118	CcSEcCtD
Leflunomide—Headache—Rosuvastatin—atherosclerosis	0.000152	0.00118	CcSEcCtD
Leflunomide—Hypersensitivity—Lovastatin—atherosclerosis	0.000152	0.00118	CcSEcCtD
Leflunomide—Decreased appetite—Pravastatin—atherosclerosis	0.000152	0.00118	CcSEcCtD
Leflunomide—Pain—Niacin—atherosclerosis	0.000151	0.00117	CcSEcCtD
Leflunomide—Fatigue—Pravastatin—atherosclerosis	0.00015	0.00117	CcSEcCtD
Leflunomide—Constipation—Pravastatin—atherosclerosis	0.000149	0.00116	CcSEcCtD
Leflunomide—Pain—Pravastatin—atherosclerosis	0.000149	0.00116	CcSEcCtD
Leflunomide—Hypersensitivity—Ezetimibe—atherosclerosis	0.000149	0.00116	CcSEcCtD
Leflunomide—Asthenia—Lovastatin—atherosclerosis	0.000148	0.00115	CcSEcCtD
Leflunomide—Pruritus—Lovastatin—atherosclerosis	0.000146	0.00113	CcSEcCtD
Leflunomide—Asthenia—Ezetimibe—atherosclerosis	0.000145	0.00113	CcSEcCtD
Leflunomide—Gastrointestinal pain—Niacin—atherosclerosis	0.000145	0.00112	CcSEcCtD
Leflunomide—Nausea—Rosuvastatin—atherosclerosis	0.000144	0.00112	CcSEcCtD
Leflunomide—Feeling abnormal—Pravastatin—atherosclerosis	0.000144	0.00111	CcSEcCtD
Leflunomide—Pruritus—Ezetimibe—atherosclerosis	0.000143	0.00111	CcSEcCtD
Leflunomide—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000143	0.00111	CcSEcCtD
Leflunomide—Hypersensitivity—Simvastatin—atherosclerosis	0.000142	0.0011	CcSEcCtD
Leflunomide—Diarrhoea—Lovastatin—atherosclerosis	0.000141	0.00109	CcSEcCtD
Leflunomide—Urticaria—Niacin—atherosclerosis	0.000141	0.00109	CcSEcCtD
Leflunomide—Body temperature increased—Niacin—atherosclerosis	0.00014	0.00109	CcSEcCtD
Leflunomide—Abdominal pain—Niacin—atherosclerosis	0.00014	0.00109	CcSEcCtD
Leflunomide—Urticaria—Pravastatin—atherosclerosis	0.000138	0.00107	CcSEcCtD
Leflunomide—Asthenia—Simvastatin—atherosclerosis	0.000138	0.00107	CcSEcCtD
Leflunomide—Diarrhoea—Ezetimibe—atherosclerosis	0.000138	0.00107	CcSEcCtD
Leflunomide—Body temperature increased—Pravastatin—atherosclerosis	0.000138	0.00107	CcSEcCtD
Leflunomide—Abdominal pain—Pravastatin—atherosclerosis	0.000138	0.00107	CcSEcCtD
Leflunomide—Pruritus—Simvastatin—atherosclerosis	0.000136	0.00106	CcSEcCtD
Leflunomide—Dizziness—Lovastatin—atherosclerosis	0.000136	0.00106	CcSEcCtD
Leflunomide—Dizziness—Ezetimibe—atherosclerosis	0.000134	0.00104	CcSEcCtD
Leflunomide—Diarrhoea—Simvastatin—atherosclerosis	0.000132	0.00102	CcSEcCtD
Leflunomide—Vomiting—Lovastatin—atherosclerosis	0.000131	0.00102	CcSEcCtD
Leflunomide—Hypersensitivity—Niacin—atherosclerosis	0.00013	0.00101	CcSEcCtD
Leflunomide—Rash—Lovastatin—atherosclerosis	0.00013	0.00101	CcSEcCtD
Leflunomide—Dermatitis—Lovastatin—atherosclerosis	0.00013	0.00101	CcSEcCtD
Leflunomide—Headache—Lovastatin—atherosclerosis	0.000129	0.001	CcSEcCtD
Leflunomide—Vomiting—Ezetimibe—atherosclerosis	0.000129	0.000998	CcSEcCtD
Leflunomide—Hypersensitivity—Pravastatin—atherosclerosis	0.000128	0.000997	CcSEcCtD
Leflunomide—Dizziness—Simvastatin—atherosclerosis	0.000128	0.00099	CcSEcCtD
Leflunomide—Rash—Ezetimibe—atherosclerosis	0.000127	0.000989	CcSEcCtD
Leflunomide—Dermatitis—Ezetimibe—atherosclerosis	0.000127	0.000988	CcSEcCtD
Leflunomide—Asthenia—Niacin—atherosclerosis	0.000127	0.000986	CcSEcCtD
Leflunomide—Headache—Ezetimibe—atherosclerosis	0.000127	0.000983	CcSEcCtD
Leflunomide—Pruritus—Niacin—atherosclerosis	0.000125	0.000972	CcSEcCtD
Leflunomide—Asthenia—Pravastatin—atherosclerosis	0.000125	0.000971	CcSEcCtD
Leflunomide—Pruritus—Pravastatin—atherosclerosis	0.000123	0.000957	CcSEcCtD
Leflunomide—Vomiting—Simvastatin—atherosclerosis	0.000123	0.000951	CcSEcCtD
Leflunomide—Nausea—Lovastatin—atherosclerosis	0.000122	0.00095	CcSEcCtD
Leflunomide—Rash—Simvastatin—atherosclerosis	0.000122	0.000944	CcSEcCtD
Leflunomide—Dermatitis—Simvastatin—atherosclerosis	0.000121	0.000943	CcSEcCtD
Leflunomide—Diarrhoea—Niacin—atherosclerosis	0.000121	0.00094	CcSEcCtD
Leflunomide—Headache—Simvastatin—atherosclerosis	0.000121	0.000937	CcSEcCtD
Leflunomide—Nausea—Ezetimibe—atherosclerosis	0.00012	0.000932	CcSEcCtD
Leflunomide—DHODH—adipose tissue—atherosclerosis	0.00012	0.166	CbGeAlD
Leflunomide—Diarrhoea—Pravastatin—atherosclerosis	0.000119	0.000926	CcSEcCtD
Leflunomide—Dizziness—Niacin—atherosclerosis	0.000117	0.000909	CcSEcCtD
Leflunomide—Dizziness—Pravastatin—atherosclerosis	0.000115	0.000895	CcSEcCtD
Leflunomide—Nausea—Simvastatin—atherosclerosis	0.000115	0.000889	CcSEcCtD
Leflunomide—Vomiting—Niacin—atherosclerosis	0.000113	0.000874	CcSEcCtD
Leflunomide—Rash—Niacin—atherosclerosis	0.000112	0.000866	CcSEcCtD
Leflunomide—Dermatitis—Niacin—atherosclerosis	0.000112	0.000866	CcSEcCtD
Leflunomide—Headache—Niacin—atherosclerosis	0.000111	0.000861	CcSEcCtD
Leflunomide—Vomiting—Pravastatin—atherosclerosis	0.000111	0.00086	CcSEcCtD
Leflunomide—Rash—Pravastatin—atherosclerosis	0.00011	0.000853	CcSEcCtD
Leflunomide—Dermatitis—Pravastatin—atherosclerosis	0.00011	0.000852	CcSEcCtD
Leflunomide—Headache—Pravastatin—atherosclerosis	0.000109	0.000848	CcSEcCtD
Leflunomide—Nausea—Niacin—atherosclerosis	0.000105	0.000816	CcSEcCtD
Leflunomide—Nausea—Pravastatin—atherosclerosis	0.000104	0.000804	CcSEcCtD
Leflunomide—PTK2B—connective tissue—atherosclerosis	9.88e-05	0.137	CbGeAlD
Leflunomide—PTK2B—cardiovascular system—atherosclerosis	8.6e-05	0.119	CbGeAlD
Leflunomide—DHODH—liver—atherosclerosis	8.39e-05	0.116	CbGeAlD
Leflunomide—PTK2B—adipose tissue—atherosclerosis	7.58e-05	0.105	CbGeAlD
Leflunomide—AHR—adipose tissue—atherosclerosis	6.23e-05	0.0864	CbGeAlD
Leflunomide—PTK2B—liver—atherosclerosis	5.32e-05	0.0737	CbGeAlD
Leflunomide—AHR—liver—atherosclerosis	4.37e-05	0.0606	CbGeAlD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—FABP4—atherosclerosis	2.54e-05	0.000416	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—LCAT—atherosclerosis	2.54e-05	0.000416	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP7A1—atherosclerosis	2.53e-05	0.000414	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—atherosclerosis	2.51e-05	0.000412	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—ALOX5AP—atherosclerosis	2.51e-05	0.000412	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—APOA2—atherosclerosis	2.51e-05	0.000412	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G2A—atherosclerosis	2.51e-05	0.000412	CbGpPWpGaD
Leflunomide—CYP2C9—cardiovascular system—atherosclerosis	2.5e-05	0.0347	CbGeAlD
Leflunomide—PTK2B—Immune System—PDGFB—atherosclerosis	2.5e-05	0.000409	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—APOA4—atherosclerosis	2.49e-05	0.000409	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—ABCG5—atherosclerosis	2.48e-05	0.000407	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP7A1—atherosclerosis	2.45e-05	0.000402	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CRP—atherosclerosis	2.44e-05	0.0004	CbGpPWpGaD
Leflunomide—ABCG2—adipose tissue—atherosclerosis	2.42e-05	0.0335	CbGeAlD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—LPA—atherosclerosis	2.4e-05	0.000393	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—HMOX1—atherosclerosis	2.39e-05	0.000392	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TLR4—atherosclerosis	2.34e-05	0.000384	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP27A1—atherosclerosis	2.34e-05	0.000383	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—APOA5—atherosclerosis	2.3e-05	0.000377	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—APOB—atherosclerosis	2.29e-05	0.000375	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP27A1—atherosclerosis	2.26e-05	0.000371	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KNG1—atherosclerosis	2.25e-05	0.000369	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ICAM1—atherosclerosis	2.24e-05	0.000368	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AGTR1—atherosclerosis	2.24e-05	0.000367	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—APOA2—atherosclerosis	2.21e-05	0.000363	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PLA2G2A—atherosclerosis	2.21e-05	0.000363	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALOX15—atherosclerosis	2.21e-05	0.000363	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALOX5AP—atherosclerosis	2.21e-05	0.000363	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G1B—atherosclerosis	2.21e-05	0.000362	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ABCG5—atherosclerosis	2.19e-05	0.000359	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—LDLRAP1—atherosclerosis	2.18e-05	0.000358	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PLG—atherosclerosis	2.18e-05	0.000358	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—APOA2—atherosclerosis	2.15e-05	0.000352	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G2A—atherosclerosis	2.15e-05	0.000352	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ALOX5AP—atherosclerosis	2.15e-05	0.000352	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—atherosclerosis	2.15e-05	0.000352	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—ALOX5—atherosclerosis	2.14e-05	0.00035	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ABCG5—atherosclerosis	2.12e-05	0.000348	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—LPA—atherosclerosis	2.11e-05	0.000346	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SOCS3—atherosclerosis	2.07e-05	0.000339	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PLTP—atherosclerosis	2.05e-05	0.000337	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—LPA—atherosclerosis	2.05e-05	0.000336	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—BGN—atherosclerosis	2.05e-05	0.000335	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—APOA5—atherosclerosis	2.03e-05	0.000332	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MMP3—atherosclerosis	2e-05	0.000327	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IGF2—atherosclerosis	1.99e-05	0.000326	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—APOA5—atherosclerosis	1.96e-05	0.000322	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PLA2G1B—atherosclerosis	1.95e-05	0.00032	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—PPARA—atherosclerosis	1.93e-05	0.000317	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—APOB—atherosclerosis	1.93e-05	0.000316	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—atherosclerosis	1.9e-05	0.000312	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EDN1—atherosclerosis	1.9e-05	0.000311	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—APOC3—atherosclerosis	1.89e-05	0.00031	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G1B—atherosclerosis	1.89e-05	0.00031	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCL5—atherosclerosis	1.88e-05	0.000309	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALOX5—atherosclerosis	1.88e-05	0.000309	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—LDLR—atherosclerosis	1.88e-05	0.000308	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—LDLRAP1—atherosclerosis	1.87e-05	0.000306	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—LPL—atherosclerosis	1.84e-05	0.000302	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CETP—atherosclerosis	1.84e-05	0.000301	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—AKT1—atherosclerosis	1.83e-05	0.0003	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ALOX5—atherosclerosis	1.82e-05	0.000299	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—APOA1—atherosclerosis	1.81e-05	0.000297	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PRKCG—atherosclerosis	1.79e-05	0.000294	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—LTA4H—atherosclerosis	1.78e-05	0.000292	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ABCG8—atherosclerosis	1.78e-05	0.000292	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—atherosclerosis	1.76e-05	0.000288	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PLTP—atherosclerosis	1.76e-05	0.000288	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SPP1—atherosclerosis	1.74e-05	0.000286	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IFNG—atherosclerosis	1.71e-05	0.00028	CbGpPWpGaD
Leflunomide—ABCG2—liver—atherosclerosis	1.7e-05	0.0235	CbGeAlD
Leflunomide—ABCG2—Metabolism—NAMPT—atherosclerosis	1.69e-05	0.000277	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—LIPC—atherosclerosis	1.68e-05	0.000275	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—APOC3—atherosclerosis	1.67e-05	0.000273	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	1.66e-05	0.000272	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—LDLR—atherosclerosis	1.66e-05	0.000272	CbGpPWpGaD
Leflunomide—CYP1A2—liver—atherosclerosis	1.63e-05	0.0226	CbGeAlD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—atherosclerosis	1.63e-05	0.000267	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CETP—atherosclerosis	1.62e-05	0.000265	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—APOC3—atherosclerosis	1.62e-05	0.000265	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PDGFB—atherosclerosis	1.61e-05	0.000265	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—LDLR—atherosclerosis	1.61e-05	0.000263	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AGT—atherosclerosis	1.58e-05	0.000258	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CETP—atherosclerosis	1.57e-05	0.000257	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SCARB1—atherosclerosis	1.55e-05	0.000254	CbGpPWpGaD
Leflunomide—CYP2C9—liver—atherosclerosis	1.55e-05	0.0215	CbGeAlD
Leflunomide—PTK2B—Signaling Pathways—APOE—atherosclerosis	1.54e-05	0.000253	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—LEP—atherosclerosis	1.54e-05	0.000253	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CAV1—atherosclerosis	1.53e-05	0.000251	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—APOA1—atherosclerosis	1.53e-05	0.00025	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL1B—atherosclerosis	1.52e-05	0.00025	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—LTA4H—atherosclerosis	1.52e-05	0.00025	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ABCG8—atherosclerosis	1.52e-05	0.00025	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—atherosclerosis	1.5e-05	0.000246	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	1.48e-05	0.000243	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ESR1—atherosclerosis	1.47e-05	0.000242	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—HMGCR—atherosclerosis	1.46e-05	0.00024	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—F2—atherosclerosis	1.46e-05	0.000239	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ALB—atherosclerosis	1.44e-05	0.000235	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—NFKB1—atherosclerosis	1.42e-05	0.000233	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	1.42e-05	0.000233	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ABCG1—atherosclerosis	1.41e-05	0.000231	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MAPK8—atherosclerosis	1.4e-05	0.000229	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CG—atherosclerosis	1.39e-05	0.000228	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—LCAT—atherosclerosis	1.32e-05	0.000217	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—FABP4—atherosclerosis	1.32e-05	0.000217	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—INS—atherosclerosis	1.32e-05	0.000216	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ABCA1—atherosclerosis	1.31e-05	0.000214	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—APOA4—atherosclerosis	1.3e-05	0.000213	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCL2—atherosclerosis	1.3e-05	0.000213	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP7A1—atherosclerosis	1.28e-05	0.000209	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—STAT3—atherosclerosis	1.28e-05	0.000209	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IGF1—atherosclerosis	1.28e-05	0.000209	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	1.26e-05	0.000207	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MAPK3—atherosclerosis	1.22e-05	0.0002	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	1.22e-05	0.000199	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SERPINE1—atherosclerosis	1.21e-05	0.000199	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ABCG1—atherosclerosis	1.2e-05	0.000197	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP27A1—atherosclerosis	1.18e-05	0.000193	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	1.16e-05	0.00019	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOS3—atherosclerosis	1.16e-05	0.00019	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	1.13e-05	0.000186	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—LCAT—atherosclerosis	1.13e-05	0.000185	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—FABP4—atherosclerosis	1.13e-05	0.000185	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—HMOX1—atherosclerosis	1.12e-05	0.000184	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—APOA2—atherosclerosis	1.12e-05	0.000183	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PLA2G2A—atherosclerosis	1.12e-05	0.000183	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALOX5AP—atherosclerosis	1.12e-05	0.000183	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALOX15—atherosclerosis	1.12e-05	0.000183	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—APOA4—atherosclerosis	1.11e-05	0.000182	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ABCG5—atherosclerosis	1.1e-05	0.000181	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	1.1e-05	0.000181	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP7A1—atherosclerosis	1.09e-05	0.000179	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—APOB—atherosclerosis	1.07e-05	0.000176	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—LPA—atherosclerosis	1.07e-05	0.000175	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTM1—atherosclerosis	1.04e-05	0.000171	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	1.04e-05	0.00017	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—BGN—atherosclerosis	1.03e-05	0.000169	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCL8—atherosclerosis	1.03e-05	0.000168	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	1.03e-05	0.000168	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—LPL—atherosclerosis	1.02e-05	0.000168	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—APOA5—atherosclerosis	1.02e-05	0.000168	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP27A1—atherosclerosis	1.01e-05	0.000165	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GPX1—atherosclerosis	9.99e-06	0.000164	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	9.94e-06	0.000163	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	9.93e-06	0.000163	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PLA2G1B—atherosclerosis	9.85e-06	0.000161	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	9.74e-06	0.00016	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CD36—atherosclerosis	9.73e-06	0.00016	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	9.68e-06	0.000159	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	9.65e-06	0.000158	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	9.62e-06	0.000158	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALOX15—atherosclerosis	9.56e-06	0.000157	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PLA2G2A—atherosclerosis	9.56e-06	0.000157	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—APOA2—atherosclerosis	9.56e-06	0.000157	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALOX5AP—atherosclerosis	9.56e-06	0.000157	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALOX5—atherosclerosis	9.51e-06	0.000156	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ABCG5—atherosclerosis	9.44e-06	0.000155	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	9.43e-06	0.000155	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MMP9—atherosclerosis	9.28e-06	0.000152	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—MTHFR—atherosclerosis	9.22e-06	0.000151	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NFKB1—atherosclerosis	9.18e-06	0.000151	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—LPA—atherosclerosis	9.12e-06	0.000149	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPARA—atherosclerosis	9.05e-06	0.000148	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAPK8—atherosclerosis	9.03e-06	0.000148	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL6—atherosclerosis	8.91e-06	0.000146	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—BGN—atherosclerosis	8.83e-06	0.000145	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	8.79e-06	0.000144	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	8.77e-06	0.000144	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AGT—atherosclerosis	8.76e-06	0.000144	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—APOA5—atherosclerosis	8.74e-06	0.000143	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—APOE—atherosclerosis	8.58e-06	0.000141	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NAMPT—atherosclerosis	8.53e-06	0.00014	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CAV1—atherosclerosis	8.51e-06	0.000139	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	8.49e-06	0.000139	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—APOA1—atherosclerosis	8.49e-06	0.000139	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	8.48e-06	0.000139	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—LIPC—atherosclerosis	8.48e-06	0.000139	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—APOC3—atherosclerosis	8.42e-06	0.000138	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PLA2G1B—atherosclerosis	8.41e-06	0.000138	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—LDLR—atherosclerosis	8.37e-06	0.000137	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—VEGFA—atherosclerosis	8.33e-06	0.000137	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	8.32e-06	0.000136	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—STAT3—atherosclerosis	8.25e-06	0.000135	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	8.24e-06	0.000135	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	8.22e-06	0.000135	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—AKT1—atherosclerosis	8.22e-06	0.000135	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CETP—atherosclerosis	8.18e-06	0.000134	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALOX5—atherosclerosis	8.13e-06	0.000133	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAPK3—atherosclerosis	7.88e-06	0.000129	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SCARB1—atherosclerosis	7.83e-06	0.000128	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CG—atherosclerosis	7.75e-06	0.000127	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TGFB1—atherosclerosis	7.65e-06	0.000125	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	7.63e-06	0.000125	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	7.51e-06	0.000123	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPARG—atherosclerosis	7.48e-06	0.000123	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HMGCR—atherosclerosis	7.4e-06	0.000121	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—INS—atherosclerosis	7.33e-06	0.00012	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NAMPT—atherosclerosis	7.29e-06	0.000119	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	7.25e-06	0.000119	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—LIPC—atherosclerosis	7.24e-06	0.000119	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—APOC3—atherosclerosis	7.2e-06	0.000118	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—LDLR—atherosclerosis	7.16e-06	0.000117	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CETP—atherosclerosis	6.99e-06	0.000115	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALB—atherosclerosis	6.72e-06	0.00011	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SCARB1—atherosclerosis	6.69e-06	0.00011	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	6.67e-06	0.000109	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ABCA1—atherosclerosis	6.59e-06	0.000108	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	6.52e-06	0.000107	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—NOS3—atherosclerosis	6.43e-06	0.000105	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HMGCR—atherosclerosis	6.32e-06	0.000104	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS2—atherosclerosis	5.88e-06	9.64e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL6—atherosclerosis	5.76e-06	9.45e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	5.7e-06	9.35e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HMOX1—atherosclerosis	5.66e-06	9.27e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ABCA1—atherosclerosis	5.63e-06	9.23e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—APOB—atherosclerosis	5.42e-06	8.88e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKT1—atherosclerosis	5.32e-06	8.72e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTM1—atherosclerosis	5.27e-06	8.64e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—LPL—atherosclerosis	5.17e-06	8.48e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GPX1—atherosclerosis	5.05e-06	8.27e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CD36—atherosclerosis	4.91e-06	8.06e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HMOX1—atherosclerosis	4.83e-06	7.92e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—MTHFR—atherosclerosis	4.66e-06	7.64e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—APOB—atherosclerosis	4.63e-06	7.59e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPARA—atherosclerosis	4.57e-06	7.49e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTM1—atherosclerosis	4.5e-06	7.38e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AGT—atherosclerosis	4.43e-06	7.25e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—LPL—atherosclerosis	4.42e-06	7.25e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—APOE—atherosclerosis	4.34e-06	7.11e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GPX1—atherosclerosis	4.31e-06	7.07e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CAV1—atherosclerosis	4.3e-06	7.04e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—APOA1—atherosclerosis	4.29e-06	7.03e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CD36—atherosclerosis	4.2e-06	6.89e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—MTHFR—atherosclerosis	3.98e-06	6.52e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CG—atherosclerosis	3.91e-06	6.42e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPARA—atherosclerosis	3.9e-06	6.4e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AGT—atherosclerosis	3.78e-06	6.2e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPARG—atherosclerosis	3.78e-06	6.19e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—APOE—atherosclerosis	3.71e-06	6.07e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—INS—atherosclerosis	3.7e-06	6.07e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CAV1—atherosclerosis	3.67e-06	6.02e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—APOA1—atherosclerosis	3.66e-06	6e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALB—atherosclerosis	3.4e-06	5.57e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CG—atherosclerosis	3.34e-06	5.48e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NOS3—atherosclerosis	3.25e-06	5.33e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPARG—atherosclerosis	3.23e-06	5.29e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—INS—atherosclerosis	3.17e-06	5.19e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS2—atherosclerosis	2.97e-06	4.87e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKT1—atherosclerosis	2.96e-06	4.85e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALB—atherosclerosis	2.9e-06	4.76e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NOS3—atherosclerosis	2.78e-06	4.55e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS2—atherosclerosis	2.54e-06	4.16e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKT1—atherosclerosis	1.49e-06	2.45e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKT1—atherosclerosis	1.28e-06	2.09e-05	CbGpPWpGaD
